Drug Design and Development for Alzheimer’s Disease
American Journal Of Pharmacy And Pharmacology · 28.02.2025 · 6 (1) · 1-16
DOI: 10.71465/ajpp.3367 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal Of Pharmacy And Pharmacology, online erschienen am 28.02.2025. Verfasst von Dr. Amelia Rhodes. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. Despite decades of research, effective curative treatments remain elusive. This article explores current strategies in drug design and development for Alzheimer’s disease, highlighting recent advancements, challenges, and future perspectives. Emphasis is placed on amyloid-beta and tau-targeting agents, cholinesterase inhibitors, NMDA receptor antagonists, and novel therapeutics emerging from precision medicine and artificial intelligence. The importance of early diagnosis, biomarkers, and blood-brain barrier permeability in drug development is also discussed. An integrated and multidisciplinary approach is essential for therapeutic breakthroughs in AD.
Zitieren
APA
Rhodes, D. A. (2025). Drug Design and Development for Alzheimer’s Disease. American Journal Of Pharmacy And Pharmacology, 6(1), 1-16. https://doi.org/10.71465/ajpp.3367
Vancouver
Rhodes DA. Drug Design and Development for Alzheimer’s Disease. American Journal Of Pharmacy And Pharmacology. 2025;6(1):1-16. doi:10.71465/ajpp.3367
BibTeX
@article{Rhodes2025,
author = {Rhodes, Dr. Amelia},
title = {Drug Design and Development for Alzheimer’s Disease},
journal = {American Journal Of Pharmacy And Pharmacology},
year = {2025},
volume = {6},
number = {1},
pages = {1--16},
doi = {10.71465/ajpp.3367}
}
EUVIMED